Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
71.75
+0.37 (0.52%)
At close: Sep 1, 2026, 4:00 PM EDT
72.20
+0.45 (0.63%)
After-hours: Sep 1, 2026, 4:31 PM EDT
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $10.13M in the quarter ending June 30, 2026, a decrease of -9.34%. This brings the company's revenue in the last twelve months to $54.59M, down -27.15% year-over-year. In the year 2025, Nektar Therapeutics had annual revenue of $55.23M, down -43.89%.
Revenue (ttm)
$54.59M
Revenue Growth
-27.15%
P/S Ratio
45.17
Revenue / Employee
$866,492
Employees
63
Market Cap
2.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 55.23M | -43.20M | -43.89% |
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
| Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
| Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
| Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
| Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
| Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
| Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
| Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
| Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
| Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
| Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
| Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
| Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
| Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
| Dec 31, 2005 | 126.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
NKTR News
- 4 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 days ago - Nektar’s rezpegaldesleukin featured in published atopic dermatitis trial - TheFly
- 7 days ago - Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 11 days ago - Nektar reinstated with a Neutral at JPMorgan - TheFly
- 16 days ago - Nektar reports Q2 EPS ($1.23), consensus ($2.04) - TheFly
- 19 days ago - Nektar Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - Nektar Therapeutics Earnings release: Q2 2026 - Filings
- 19 days ago - Nektar Therapeutics Quarterly report: Q2 2026 - Filings